Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study.
Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of...
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2022 |
| País: | España |
| Institución: | INCLIVA |
| Repositorio: | r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| OAI Identifier: | oai:incliva.fundanetsuite.com:p16751 |
| Acceso en línea: | https://incliva.portalinvestigacion.com/publicaciones/16751 |
| Access Level: | acceso abierto |
| id |
ES_a2f4fe8fbd64e3a2011cc89618a50876 |
|---|---|
| oai_identifier_str |
oai:incliva.fundanetsuite.com:p16751 |
| network_acronym_str |
ES |
| network_name_str |
España |
| spelling |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. Troya, Jesus Duenas, Carlos Irazola, Idoia de Los Santos, Ignacio de la Fuente, Sara Gil, Desire Hernandez, Cristina Galindo, Maria Jose Gomez, Julia Delgado, Elisabeth Moreno-Garcia, Estela Posada, Guillermo Aldamiz, Teresa Iribarren, Jose Antonio Guerra, Jose Manuel Moran, Miguel Angel Galera, Carlos Fuente, Javier Pelaez, Ana Cervero, Miguel Garcinuno, Maria Montero, Marta Ceballos, Francisco Buzon, Luis Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data.A multicentric retrospective cohort study.Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment.The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR -40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = -23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age.In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control. LIPPINCOTT WILLIAMS & WILKINS https://incliva.portalinvestigacion.com/publicaciones/16751 |
| title |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| spellingShingle |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. Troya, Jesus |
| title_short |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| title_full |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| title_fullStr |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| title_full_unstemmed |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| title_sort |
Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study. |
| author |
Troya, Jesus |
| author_facet |
Troya, Jesus Duenas, Carlos Irazola, Idoia de Los Santos, Ignacio de la Fuente, Sara Gil, Desire Hernandez, Cristina Galindo, Maria Jose Gomez, Julia Delgado, Elisabeth Moreno-Garcia, Estela Posada, Guillermo Aldamiz, Teresa Iribarren, Jose Antonio Guerra, Jose Manuel Moran, Miguel Angel Galera, Carlos Fuente, Javier Pelaez, Ana Cervero, Miguel Garcinuno, Maria Montero, Marta Ceballos, Francisco Buzon, Luis |
| author_role |
author |
| author2 |
Duenas, Carlos Irazola, Idoia de Los Santos, Ignacio de la Fuente, Sara Gil, Desire Hernandez, Cristina Galindo, Maria Jose Gomez, Julia Delgado, Elisabeth Moreno-Garcia, Estela Posada, Guillermo Aldamiz, Teresa Iribarren, Jose Antonio Guerra, Jose Manuel Moran, Miguel Angel Galera, Carlos Fuente, Javier Pelaez, Ana Cervero, Miguel Garcinuno, Maria Montero, Marta Ceballos, Francisco Buzon, Luis |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author |
| description |
Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of clinical practice data.A multicentric retrospective cohort study.Treatment-experienced virologically suppressed HIV-1-infected patients who were switched to DTG plus RPV were included. Using different models for paired data, we evaluated the efficacy and immune status in terms of CD4+ and CD8+ T-cell counts and CD4/CD8 ratio at 24 and 48 weeks of treatment.The study population comprised of 524 patients from 34 centers in Spain. Men accounted for 76.9% of patients, with a median age of 53 years. Patients receiving DTG plus RPV reached weeks 24 and 48 in 99.4% and 83.8% of cases, respectively, with only three (0.57%) virological failures. We found a significant decrease in CD8+ T-cell count (log OR -40) at week 24 and an increase in CD4+ T-cell count at week 48 (log OR +22.8). In acquired immunodeficiency syndrome-diagnosed patients, we found a significant increase in the CD4+ T-cell count at week 48 (log OR = 41.7, P = .0038), but no significant changes in the CD8+ T-cell count (log OR = -23.4, P = .54). No differences were found in the CD4/CD8 ratio between the acquired immunodeficiency syndrome subgroup and sex or age.In patients with controlled treatment, dual therapy with DTG plus RPV slightly improved the immune status during the first 48 weeks after switching, not only in terms of CD4+ T-cell count but also in terms of CD8+ T-cell count, with persistently high rates of viral control. |
| publishDate |
2022 |
| format |
article |
| status_str |
publishedVersion |
| url |
https://incliva.portalinvestigacion.com/publicaciones/16751 |
| eu_rights_str_mv |
openAccess |
| publisher |
LIPPINCOTT WILLIAMS & WILKINS |
| institution |
INCLIVA |
| collection |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| reponame_str |
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA |
| instname_str |
INCLIVA |
| _version_ |
1878438744518819840 |
| publishDateSort |
2022 |
| author_browse |
Aldamiz, Teresa Buzon, Luis Ceballos, Francisco Cervero, Miguel Delgado, Elisabeth Duenas, Carlos Fuente, Javier Galera, Carlos Galindo, Maria Jose Garcinuno, Maria Gil, Desire Gomez, Julia Guerra, Jose Manuel Hernandez, Cristina Irazola, Idoia Iribarren, Jose Antonio Montero, Marta Moran, Miguel Angel Moreno-Garcia, Estela Pelaez, Ana Posada, Guillermo Troya, Jesus de Los Santos, Ignacio de la Fuente, Sara |
| publisherStr |
LIPPINCOTT WILLIAMS & WILKINS |
| score |
6,924472 |